Image Source: DepositPhotos

Aurora Cannabis (ACB), a constituent in the MunAiMarkets Canadian Cannabis LP Stocks Portfolio, issued a strong denial yesterday of two  reports published June 18th on Investing.com - allegedly created with the support of AI and reviewed by an editor - claiming the company:

• had agreed to acquire New Zealand-based MedLeaf Therapeutics in a $215 million cash and stock deal and
• had announced a new partnership with MediPharm GmbH to distribute medical cannabis in Europe.

Aurora stated unequivocally that:

• no such agreements or discussions have occurred and that
• it has not filed or disclosed any information supporting these claims and 
• it holds no material non-public information.

It stated that any legitimate announcements, if any, will be made directly through official channels. Aurora is investigating the origin of the misinformation and warned investors not to treat Investing.com as a reliable source for corporate news. For the record, an Investing.com spokesperson stated that the articles in question were published due to a technical issue and were immediately removed upon receiving notice on Thursday.

The above disinformation (fake news) had a chilling affect on ACB's stock price on Friday, dropping 12.8% on top of a 20.4% decline on Wednesday ( (see here), with its disappointing Q4 results and cautious Q1 guidance. As such, the  stock was down 13.2% week ending June 20th and is now down 4.0% YTD.

About Aurora Cannabis

Aurora Cannabis Inc. engages in the production, distribution, and sale of cannabis and cannabis-derivative products in Canada and internationally. Specifically, it cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, dried flowers, vapes, dried milled strains, edibles, concentrates, and strain specific cannabis oils and extracts.
 

Aurora Cannabis Analyst Stock Forecasts and Ratings

Currently there is no analyst price target forecast available for Aurora Cannabis, but 1 analyst rates ACB as a "Hold" suggesting that ACB is likely to perform similarly to the overall market.

More By This Author:

Aurora Cannabis Fell 20% On Wednesday - Here's Why
Micron Technology Continues To Surge: Up Another 22% Already In June - Here's Why
Recursion Pharmaceuticals Went Down 10% Week-Ending June 13th - Here's Why